Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy

[1]  A. Wolff,et al.  Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population‐based study among older breast cancer patients , 2018, Cancer.

[2]  Haitao Zhao,et al.  Response of BRCA1-mutated gallbladder cancer to olaparib: A case report , 2016, World journal of gastroenterology.

[3]  A. Sinha,et al.  Detection of high frequency of mutations in a breast and/or ovarian cancer cohort: implications of embracing a multi-gene panel in molecular diagnosis in India , 2016, Journal of Human Genetics.

[4]  T. Walsh,et al.  Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy‐related leukemia , 2016, Cancer.

[5]  L. Neumayer,et al.  Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Falini,et al.  Clustering of genomic breakpoints at the MLL locus in therapy‐related acute leukemia with t(4;11)(q21;q23) , 2014, Genes, chromosomes & cancer.

[7]  E. Rosenthal,et al.  Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry , 2014, Breast Cancer Research and Treatment.

[8]  F. Lo‐Coco,et al.  Biology and management of therapy-related acute promyelocytic leukemia , 2013, Current opinion in oncology.

[9]  Paola Fazi,et al.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.

[10]  M. Tucker,et al.  Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. , 2013, Blood.

[11]  S. Devesa,et al.  Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. , 2012, Blood.

[12]  Elias Campo,et al.  The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. , 2011, Blood.

[13]  R. Schlenk,et al.  Analysis of t(15;17) chromosomal breakpoint sequences in therapy‐related versus de novo acute promyelocytic leukemia: Association of DNA breaks with specific DNA motifs at PML and RARA loci , 2010, Genes, chromosomes & cancer.

[14]  R. Strair,et al.  Acute Myelogenous Leukemia and Myelodysplasia Secondary to Breast Cancer Treatment: Case Studies and Literature Review , 2010, The American journal of the medical sciences.

[15]  S. Corey,et al.  Pediatric Therapy-related Myelodysplastic Syndrome/Acute Myeloid Leukemia: The MD Anderson Cancer Center Experience , 2009, Journal of pediatric hematology/oncology.

[16]  M. Ellis,et al.  Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study , 2009, Breast Cancer Research and Treatment.

[17]  F. Lo‐Coco,et al.  Identification of a potential “hotspot” DNA region in the RUNX1 gene targeted by mitoxantrone in therapy‐related acute myeloid leukemia with t(16;21) translocation , 2009, Genes, chromosomes & cancer.

[18]  J. Esteve,et al.  Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. , 2008, Blood.

[19]  Christian Urban,et al.  Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. , 2007, Blood.

[20]  J. Bergh,et al.  Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Segal,et al.  DNA topoisomerase II in therapy-related acute promyelocytic leukemia. , 2005, The New England journal of medicine.

[22]  H. Cavé,et al.  Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.

[23]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[24]  E. Macintyre,et al.  Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease , 1999, Leukemia.

[25]  R N Hoover,et al.  Risk of leukemia after chemotherapy and radiation treatment for breast cancer. , 1992, The New England journal of medicine.